N C gains $7 million from opioid settlement journalnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journalnow.com Daily Mail and Mail on Sunday newspapers.
In the worst case, forecasts 2021 sales of $565 mln 2020 sales fall 18%, swings to operating loss on legal hit Shares down 1.3% in early trade (Adds details on legal settlements, newer drugs)
Feb 18 (Reuters) - Opioid addiction treatment maker Indivior on Thursday predicted 2021 revenue would slip on a difficult first-half after sales fell 18% this year due to cheaper rivals to its best-selling drug and disruption from the COVID-19 pandemic.
The company expects net revenue of up to $625 million, assuming that coronavirus restrictions that have kept patients away from hospitals and limited access to medicines will be lifted in the second half.
However, if those restrictions persist, net revenue is seen at $565 million, sending the London-listed company’s shares 1.3% lower at 147 pence in early trading.